Loading...
XLON
HLMA
Market cap18bUSD
Aug 28, Last price  
3,632.00GBP
Name

Halma PLC

Chart & performance

D1W1MN
XLON:HLMA chart
P/E
36.85
P/S
5.31
EPS
0.99
Div yield, %
0.65%
Shrs. gr., 5y
Rev. gr., 5y
14.39%
Revenues
Net income
CFO
Dividend
Jul 09, 202615.11 GBP/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1894 and based in Amersham, UK, Halma plc is a global group of companies delivering innovative technological products and services across three primary areas: safety, health, and environmental protection. These operations are structured into three distinct segments: Safety, Environmental & Analysis, and Medical. The Safety division focuses on preventing harm and managing risk; its offerings include advanced fire detection and suppression systems, secure elevator operation technologies, various security sensors, solutions for managing human and vehicular traffic, specialized interlocks to ensure safe critical process control, and protective measures against explosions and corrosion. This segment caters to a broad range of industries, such as elevator safety, fire management, access control for industrial settings, secure storage and material transfer, and general people and vehicle movement. Within the Environmental & Analysis segment, Halma develops and supplies technologies for understanding and protecting our surroundings, encompassing sophisticated optical and imaging systems, comprehensive monitoring solutions for water, air, and various gases, devices for identifying dangerous gases and assessing air quality, and advanced systems for water purification and analysis. Key markets for this segment include optical diagnostics, water management, gas sensing, and overall environmental observation. The Medical division is dedicated to supporting healthcare and life sciences; it delivers essential fluidic components for medical diagnostic equipment and OEMs, along with laboratory instruments and systems that generate vital patient health data to guide treatment decisions. This segment also provides technologies and solutions that facilitate in-vitro diagnostics, accelerate life-science research and development, and improve patient outcomes across diverse clinical fields. Its primary markets are life sciences, health evaluation, and therapeutic interventions.
IPO date
Jan 03, 1986
Employees
8,000
Domiciled in
GB
Incorporated in
GB

Valuation

No data to show